The Pattern of Pharmacological Treatment in Subjects with Metabolic Syndrome: Findings from Isfahan Healthy Heart Program

• Main Authors: Mojgan Gharipour, Afshan Akhavan TAbib, Nafiseh Toghianifar, Aliakbar Tavassoli, Amin Gharipour, Nizal Sarrafzadegan
• Format: Article
• Language: fas
• Published: Vesnu Publications 2011-07-01
• Series: مجله دانشکده پزشکی اصفهان
• Subjects: Metabolic syndrome; Iran; Pharmacological treatment
• Online Access: http://jims.mui.ac.ir/index.php/jims/article/view/1011

Background: Pharmacological therapy is a critical step in the management of individuals with Metabolic Syndrome (MetS) when lifestyle modifications can not to achieve the therapeutic goals. However, it is well-documented that other than weight loss, there is no single best therapy, and the treatment should consist of treatment of individual components of the MetS. The objective of this study was to investigate treatment of individual components of the MetS among a population–based sample of individuals with the clustering of those components of the MetS. Methods: A cross-sectional population-based study, a randomly collected sample of men and women living in three counties in central Iran participating in the baseline survey of a community –based program in 2000-2001 were examined. A questionnaire was completed for all participants to collect data regarding their demographic characteristics, medical status and history of medication use. In this study we determined the association between clustering of MetS components and pharmacological treatment of cardiovascular risk factors. Finding: The most common pharmacologic agent received by individuals with MetS were beta blockers (72.8%) used for controlling high blood pressure, followed by lipid lowering agents (36%) without significant gender difference. Conclusion: Our results exhibited Beta blockers, statins, fibrates and glybenclamid are more prevalent drugs among subjects with metabolic syndrome. Further research is needed to better elucidate the compliance behavior of patients who have been diagnosed with MetS.